IN BRIEF: MaxCyte hires chief scientist from Stemson Therapeutics

Archived article

Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.

MaxCyte Inc - Maryland-based platform for cell-based research - Hires Cenk Sumen as chief scientific officer. Sumen joins from San Diego, California-based hair-loss treatment firm Stemson Therapeutics Corp, where he was chief technology officer.

Current stock price: 420.00 pence

12-month change: down 51%

Copyright 2022 Alliance News Limited. All Rights Reserved.